Скачать или смотреть Stanford Psychedelic Science Group Presents: Dr. Josh Woolley

Dr. Woolley's presentation offers an overview of psilocybin therapy
(PT), focusing on its potential for treating conditions like major depressive disorder and bipolar II depression. He highlights key challenges, such as the high cost of two-therapist models, masking limitations in trials, and managing patient expectations, while examining the impact of regulatory changes and media. Ethical and methodological concerns, particularly the need for robust trial designs, are also discussed. Dr. Woolley reviews his team's recent JAMA Psychiatry paper, which explores modified informed consent to address functional unmasking in psychedelic trials, aiming to improve reliability and reduce expectancy biases. The presentation advocates for innovations that enhance the safety, effectiveness, and
equity of psychedelic-assisted therapies.